Evidence map›Paper›PMID 41353517›Full record

ArticleBone marrow transplantation2026

Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia.

Klaus Wethmar, Matthias Edinger, Kerstin Schäfer-Eckart, Matthias Stelljes, Thomas Schroeder, Kristina Sohlbach, Renate Arnold, Michael Stadler, Gesine Bug, Martin Bornhäuser and 10 more

Abstract readMulticenter Study
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Klaus WethmarDepartment of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany. Klaus.Wethmar@ukmuenster.de.ORCID 0000-0002-1899-3261
Matthias EdingerDepartment of Internal Medicine III (Hematology and Oncology), University Hospital Regensburg, Regensburg, Germany and Leibniz-Institute for Immunotherapy, Regensburg, Germany.
Kerstin Schäfer-EckartDepartment of Internal Medicine 5, Klinikum Nürnberg, Paracelsus Medizinische Privatuniversität, Nürnberg, Germany.
Matthias StelljesDepartment of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany.ORCID 0000-0002-9331-5145
Thomas SchroederDepartment of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
Kristina SohlbachDepartment of Internal Medicine, Hematology, Oncology and Immunology, University Hospital Giessen and Marburg, Marburg, Germany.
Renate ArnoldHematology and Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Michael StadlerHematology & Oncology, Medical Center University of Hannover, Hannover, Germany.
Gesine BugGoethe University, University Hospital, Department of Medicine II, Hematology/Oncology, Frankfurt, Germany.ORCID 0000-0003-2359-131X
Martin BornhäuserDepartment of Internal Medicine I, Carl Gustav Carus University Hospital Dresden, TU Dresden, Dresden, Germany.
Gerald WulfDepartment of Hematology and Oncology, Georg-August University Göttingen, Göttingen, Germany.
Wolfgang BethgeDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0001-6052-2618
Edgar JostDepartment of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
Daniel TeschnerDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Guido KobbeDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.ORCID 0000-0002-9745-8813
Monika BrüggemannDepartment of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany.ORCID 0000-0001-5514-5010
Lena ReiserGoethe University, University Hospital, Department of Medicine II, Hematology/Oncology, Frankfurt, Germany.
Dieter HoelzerGoethe University, University Hospital, Department of Medicine II, Hematology/Oncology, Frankfurt, Germany.
Nicola Gökbuget *Goethe University, University Hospital, Department of Medicine II, Hematology/Oncology, Frankfurt, Germany.
Stefan Schönland *Department of Medicine V, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0002-4853-5579

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Total body irradiation (TBI) plus chemotherapy is commonly applied prior to allogeneic hematopoietic stem cell transplantation (SCT) for patients with acute lymphoblastic leukemia (ALL). Here, we retrospectively analyzed registry data from the German Multicenter Study Group for Adult ALL (GMALL) and report the outcomes for 111 adult ALL patients who received 8 Gy TBI-based SCT conditioning in first complete remission between 2002 and 2018 after initial treatment with pediatric-based approaches. Patients had a median age of 52 years (range 18-65) at initial diagnosis, and the majority of patients (93%) had a good performance status (ECOG 0/1). 97 patients (87%) showed high-risk features according to GMALL criteria, of whom 58 (60%) were Philadelphia chromosome/BCR::ABL1-positive. With a median follow-up of 3.1 years after SCT, the survival rates at one, three, and five years were 72%, 64%, and 57% for disease-free survival, and 76%, 67%, and 61% for overall survival, respectively. The rates of non-relapse mortality at one, three, and five years were 22%, 26%, and 30%, while the cumulative incidences of relapse were 7%, 10%, and 14%, respectively. In summary, 8 Gy TBI conditioning in ALL patients was feasible and resulted in outcomes similar to those previously reported for 12 Gy conditioning regimens.

Indexed as

Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningWhole-Body IrradiationAdolescentAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesYoung Adult

Identifiers

PMID41353517
PMCPMC12965881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.